- 作者：Riccardo Giampieri ; Mario Scartozzi ; Michela Del Prete ; Elena Maccaroni ; Aless ; ro Bittoni ; Luca Faloppi ; Maristella Bianconi ; Luca Cecchini ; Stefano Cascinu
- 关键词：Anti-EGFR ; Biomarkers ; Colorectal cancer ; Resistance
- 刊名：Critical Reviews in Oncology/Hematology
- 出版年：2013
- 出版时间：November, 2013
- 年：2013
- 卷：88
- 期：2
- 页码：272-283
- 全文大小：984 K
Background
Systematic dissection of the EGFR pathway was considered as the best way to identify putative markers of resistance to anti-EGFR therapies. This kind of approach leaves other, less known but by no means less important, putative mechanisms of resistance. We tried to shed some light on these mechanisms of resistance.Materials and methods
We performed a research through Pubmed database of all published articles highlighting mechanisms of resistance to Cetuximab and Panitumumab based therapies, published in 2000-2012 period.
Conclusions
We reviewed the ¡°classical¡± molecular factors, extensively analyzed as predictive factors for efficacy to anti-EGFR therapy, such as K-ras, B-raf, and PI3K-mTOR-Akt, focusing on their predictive or prognostic value and on the controversial aspects of the biomarker analysis for clinical practice. On the second part we will then move on to other less known molecular markers, for the future understanding of biological mechanisms underlying anti-EGFR therapy resistance, such as non-canonical heterodimer candidates, microRNA, IGF1-IGF1R, HGF-cMET and secondary mutations of EGFR.